UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 71

Sortiert nach

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

Annals of hematology, 2022-05, Vol.101 (5), p.963-978

2022

Volltextzugriff (PDF)

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS

Proceedings of the National Academy of Sciences - PNAS, 2009-09, Vol.106 (39), p.16811-16816

2009

Volltextzugriff (PDF)

Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes

Current pharmaceutical design, 2016-05, Vol.22 (16), p.2349

2016

Volltextzugriff (PDF)

Phosphoinositide-Phospholipase C β1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia

Journal of clinical oncology, 2009-02, Vol.27 (5), p.782-790

2009

Volltextzugriff (PDF)

Nuclear inositide signaling in myelodysplastic syndromes

Journal of cellular biochemistry, 2010-04, Vol.109 (6), p.1065-1071

2010

Volltextzugriff (PDF)

Advancement in high dose therapy and autologous stem cell rescue in lymphoma

World journal of stem cells, 2015-08, Vol.7 (7), p.1039-1046

2015

Volltextzugriff (PDF)

The myelodysplastic syndromes: diagnosis, prognosis and therapy

Italian journal of medicine, 2013-03, Vol.5 (2), p.90-97

2013

Volltextzugriff (PDF)

Deferasirox Boosts Hematopoietic Recovery after ALLO-Sct

Blood, 2017-12, Vol.130, p.5463-5463

2017

Volltextzugriff (PDF)

Nuclear translocation of PKC‐ α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs)

The FASEB journal, 2018-02, Vol.32 (2), p.681-692

2018

Volltextzugriff (PDF)

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes

Clinical cancer research, 2013-06, Vol.19 (12), p.3297-3308

2013

Volltextzugriff (PDF)

An increased expression of PI-PLC beta 1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes

Journal of leukocyte biology, 2015-11, Vol.98 (5), p.769-780

2015

Volltextzugriff (PDF)

An increased expression of PI‐PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes

Journal of leukocyte biology, 2015-11, Vol.98 (5), p.769-780

2015

Volltextzugriff (PDF)

Soluble RAGE in type 2 diabetes: Association with oxidative stress

Free radical biology & medicine, 2007-08, Vol.43 (4), p.511-518

2007

Volltextzugriff (PDF)

Computed Tomographic Pulmonary Angiography for Diagnosis of Invasive Mold Diseases in Patients With Hematological Malignancies

Clinical infectious diseases, 2012-03, Vol.54 (5), p.610-616

2012

Volltextzugriff (PDF)

Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study

British journal of haematology, 2017-06, Vol.177 (5), p.741-750

2017

Volltextzugriff (PDF)

The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment

Expert review of hematology, 2014-12, Vol.7 (6), p.807-818

2014

Volltextzugriff (PDF)

P-129 Real world evidence of prognostic impact of t(14;16) translocation in multiple myeloma: a report of the myeloma triveneto working group

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S106-S107

2023

Volltextzugriff (PDF)

Enteric‐coated mycophenolate sodium: a new option for GHVD prophylaxis?

European journal of haematology, 2017-04, Vol.98 (4), p.320-321

2017

Volltextzugriff (PDF)

PBSC mobilization in patients with autoimmune diseases: what's next

European journal of haematology, 2016-07, Vol.97 (1), p.5-6

2016

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(71)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Humans
(22)
Life Sciences & Biomedicine
(22)
Hematology
(10)
Female
(9)
Aged
(8)
Male
(8)
Middle Aged
(8)
Aged, 80 And Over
(7)
Animals
(6)
Myelodysplastic Syndromes - Drug Therapy
(6)
Adult
(5)
Myelodysplastic Syndromes
(5)
Oncology
(5)
Biochemistry & Molecular Biology
(4)
Cell Biology
(4)
Disease Progression
(4)
Immunotherapy
(4)
Signal Transduction
(4)
Epigenetic Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS

Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience

P970: A REAL‐WORLD RETROSPECTIVE‐PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE

PB2611: EVANS SYNDROME: DISEASE AWARENESS AND CLINICAL MANAGEMENT IN A NATION‐WIDE ITALIAN SURVEY

Phosphoinositide-Phospholipase C β1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia

Nuclear inositide signaling in myelodysplastic syndromes

Advancement in high dose therapy and autologous stem cell rescue in lymphoma

The myelodysplastic syndromes: diagnosis, prognosis and therapy

Deferasirox Boosts Hematopoietic Recovery after ALLO-Sct

Evans syndrome: Disease awareness and clinical management in a nation‐wide ITP ‐ NET survey

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group

Nuclear translocation of PKC‐ α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs)

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes

An increased expression of PI-PLC beta 1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes

An increased expression of PI‐PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes

Soluble RAGE in type 2 diabetes: Association with oxidative stress

Computed Tomographic Pulmonary Angiography for Diagnosis of Invasive Mold Diseases in Patients With Hematological Malignancies

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study

The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment

P-129 Real world evidence of prognostic impact of t(14;16) translocation in multiple myeloma: a report of the myeloma triveneto working group

Enteric‐coated mycophenolate sodium: a new option for GHVD prophylaxis?

PBSC mobilization in patients with autoimmune diseases: what's next

Suchergebnisse filtern